ArticlesPricing

Products

See All Solutions →
By ProductEMARKETER PRO+Analyst Access Program
By Use CaseDetermine Market SizingDevelop StrategiesAllocate BudgetBenchmark PerformanceWin New BusinessDevelop Go-to-Market StrategyStay InformedThought LeadershipSee All Use Cases →
Advertising & Sponsorship
Boost your brand and generate demand with media programs.
Learn More →

Events & Resources

Learning Center
Read through guides, explore resource hubs, and sample our coverage.
Learn More →
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More →
Podcasts
Listen to our podcast, Behind the Numbers for the latest news and insights.
Learn More →

Topics

See All Topics →
Advertising & MarketingSocial MediaContent MarketingEmail MarketingVideoBrowse All →
Ecommerce & RetailEcommerce SalesMcommerceRetail SalesSocial CommerceBrowse All →
Financial ServicesBankingPaymentsFintechWealth ManagementBrowse All →
GeographiesAsia-PacificCentral & Eastern EuropeLatin AmericaMiddle East & AfricaNorth AmericaWestern Europe
HealthValue-Based CareDigital TherapeuticsTelehealthOnline PharmacyBrowse All →
TechnologyConnected Devices5GArtificial Intelligence (AI)Browse All →
More IndustriesReal EstateCustomer ExperienceB2BTravelSmall Business (SMB)Browse All →

Latest Articles

Explore our Research →

The big answers: EMARKETER Daily quiz

Article |
 Aug 1, 2025

Revolut could soon become a full-service US bank

Article |
 Aug 1, 2025

Nano-influencers earn impressive impression, engagement rates

Article |
 Aug 1, 2025

JPMorgan-Coinbase partnership could change customers’ relationship with crypto

Article |
 Aug 1, 2025

Trump intensifies threats against pharma if drugmakers don’t lower US prices

Article |
 Aug 1, 2025

AI streamlines health report filings in Merck, McKinsey collab

Article |
 Aug 1, 2025

United tries time-sensitive travel promotions to boost cardholder bookings

Article |
 Aug 1, 2025

Klarna mulls possible September IPO

Article |
 Aug 1, 2025

Competitive conquesting gains ground among RMNs

Article |
 Jul 31, 2025

Parents prioritize value, convenience during back-to-school shopping

Article |
 Jul 31, 2025
Browse All →

About

Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More →
Our Clients
Key decision-makers share why they find EMARKETER so critical.
Learn More →
Our People
Take a look into our corporate culture and view our open roles.
Join the Team →
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More →
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More →
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us →
EMARKETER

Sales of Mounjaro and Zepbound missed estimates in Q3

Article by Rajiv Leventhal  |  Nov 1, 2024
Download
Sales of Mounjaro and Zepbound missed estimates in Q3
Share
Topics
Digital Health
United States

The news: Eli Lilly reported weaker-than-expected sales in Q3 for its two GLP-1 blockbuster medications, Mounjaro and Zepbound.

  • For Q3 2024, worldwide Mounjaro revenues were $3.11 billion, while Zepbound brought in $1.26 billion in the US.
  • Analysts expected Mounjaro sales at $4.2 billion and $1.69 billion for Zepbound, according to LSEG data cited by Reuters.
  • Zepbound sales slightly decreased quarter over quarter, while sales for Mounjaro slightly increased.

You've read 0 of 2 free articles this month.

Create an account for uninterrupted access to select articles.
Create a Free Account